LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 1 | I02 | 72 | hr | 1476 | 1921 | 3694 | 0.5200 | 0.2004 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 2 | I02 | 72 | hr | 1476 | 2063 | 3694 | 0.5585 | 0.2644 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 3 | I02 | 72 | hr | 1476 | 1907 | 3694 | 0.5162 | 0.1941 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 1 | E20 | 72 | hr | 1476 | 1919 | 3694 | 0.5195 | 0.1995 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 2 | E20 | 72 | hr | 1476 | 1894 | 3694 | 0.5127 | 0.1882 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 3 | E20 | 72 | hr | 1476 | 2051 | 3694 | 0.5552 | 0.2590 |
| SK-BR-3 | Enzastaurin | 3.33 | uM | LJP5 | 1 | D14 | 72 | hr | 1476 | 4060 | 3694 | 1.0991 | 1.1650 |
| SK-BR-3 | Enzastaurin | 3.33 | uM | LJP5 | 2 | D14 | 72 | hr | 1476 | 4091 | 3694 | 1.1075 | 1.1790 |
| SK-BR-3 | Enzastaurin | 3.33 | uM | LJP5 | 3 | D14 | 72 | hr | 1476 | 4012 | 3694 | 1.0861 | 1.1434 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 1 | M20 | 72 | hr | 1476 | 3294 | 3694 | 0.8917 | 0.8196 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 2 | M20 | 72 | hr | 1476 | 3152 | 3694 | 0.8533 | 0.7555 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 3 | M20 | 72 | hr | 1476 | 3402 | 3694 | 0.9209 | 0.8683 |
| SK-BR-3 | Foretinib | 3.33 | uM | LJP5 | 1 | H08 | 72 | hr | 1476 | 1471 | 3694 | 0.3982 | -0.0026 |
| SK-BR-3 | Foretinib | 3.33 | uM | LJP5 | 2 | H08 | 72 | hr | 1476 | 1485 | 3694 | 0.4020 | 0.0037 |
| SK-BR-3 | Foretinib | 3.33 | uM | LJP5 | 3 | H08 | 72 | hr | 1476 | 1408 | 3694 | 0.3812 | -0.0310 |
| SK-BR-3 | R406 | 3.33 | uM | LJP6 | 1 | C14 | 72 | hr | 1476 | 3816 | 3694 | 1.0330 | 1.0550 |
| SK-BR-3 | R406 | 3.33 | uM | LJP6 | 2 | C14 | 72 | hr | 1476 | 4349 | 3694 | 1.1773 | 1.2954 |
| SK-BR-3 | R406 | 3.33 | uM | LJP6 | 3 | C14 | 72 | hr | 1476 | 4331 | 3694 | 1.1724 | 1.2873 |
| SK-BR-3 | Pictilisib | 3.33 | uM | LJP6 | 1 | D20 | 72 | hr | 1476 | 1656 | 3694 | 0.4483 | 0.0809 |
| SK-BR-3 | Pictilisib | 3.33 | uM | LJP6 | 2 | D20 | 72 | hr | 1476 | 1625 | 3694 | 0.4399 | 0.0669 |
| SK-BR-3 | Pictilisib | 3.33 | uM | LJP6 | 3 | D20 | 72 | hr | 1476 | 1726 | 3694 | 0.4672 | 0.1124 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 1 | N08 | 72 | hr | 1476 | 1869 | 3694 | 0.5060 | 0.1769 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 2 | N08 | 72 | hr | 1476 | 2074 | 3694 | 0.5614 | 0.2694 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 3 | N08 | 72 | hr | 1476 | 2136 | 3694 | 0.5782 | 0.2973 |
| SK-BR-3 | Geldanamycin | 3.33 | uM | LJP5 | 1 | O02 | 72 | hr | 1476 | 1293 | 3694 | 0.3500 | -0.0829 |